PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 25, 2026Journal of Medical Economics0 citationsOpen Access

Real-world treatment switching and healthcare costs of onabotulinumtoxinA and calcitonin gene-related peptide monoclonal antibodies in Medicare patients with chronic migraine: a retrospective claims analysis

View Full Paper
YDYanan DongZMZiling MaoADAnnaliza Dominguez

Key Points

  • The aim is to evaluate treatment switching and associated healthcare costs in Medicare patients with chronic migraine receiving onabotulinumtoxinA or CGRP monoclonal antibodies.
  • Retrospective claims analysis of Medicare patients
  • Comparison of treatment switch rates between onabotulinumtoxinA and CGRP mAb
  • Cost analysis for both treatment groups
  • Patients on CGRP mAb are more likely to switch migraine treatments within the first 12 months than those on onabotulinumtoxinA.
  • Total healthcare costs for both treatments appear comparable.

Abstract

Patients with CM on a CGRP mAb were significantly more likely to switch to a different branded migraine preventive treatment within 12 months of treatment initiation compared to those on onabotA. Total costs were comparable between treatments.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Dong et al. (2026) studied this question.

synapsesocial.com/papers/699e919cf5123be5ed04f36fhttps://doi.org/10.1080/13696998.2026.2630604
Ask AI
Helpful
Bookmark
Share
View Full Paper